BIT 2.22% 4.6¢ biotron limited

$10 Billion Deal, page-130

  1. 16,259 Posts.
    lightbulb Created with Sketch. 742
    The BIT drug trial mentions no effect on CD4+ T cells which are the main barrier to a cure.



    https://www.genengnews.com/topics/g...tent-hiv-1-offering-hope-of-functional-cures/



    CD4+ T cells have been the most studied of the cellular reservoirs in which HIV-1 can persist. A small fraction of resting CD4+ T cells will harbor HIV-1, even during ART, and are considered to be “the major obstacle to HIV-1 eradication,” the authors point out. “Latent HIV-1 infection in resting CD4+ T cells is the primary cause of the barrier to a functional cure.”
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
4.6¢
Change
0.001(2.22%)
Mkt cap ! $41.50M
Open High Low Value Volume
4.4¢ 4.7¢ 4.4¢ $31.64K 708.3K

Buyers (Bids)

No. Vol. Price($)
4 259000 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.6¢ 17361 1
View Market Depth
Last trade - 14.10pm 21/06/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.